1186 results about "Antigenicity" patented technology

The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.

A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.

The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

The present invention relates to the display of antigenic or allergenic components along with a tissue-targeting component on viruses or virus-like particles. Capsid protein genes are recombinantly modified to contain the specified components then expressed within a host organism, such as yeasts, bacteria, or algae, and allowed to spontaneously form active virus particles or virus-like particles. The recombinant complexes (virus or virus-like particle) can then be purified or used in situ as a therapeutic tool for disease or allergy prevention. The expression of multivalent and multifunctional components to increase the immunogenicity of the recombinant complexes, especially on oral administration, is provided.

The present invention relates to pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, infectious diseases, neurodegenerative diseases, and primary and metastatic neoplastic diseases. In the practice of the invention, the compositions are employed comprising: (a) a heat shock protein (hsp) or an alpha(2)macroglobulin (alpha2M); (b) a saponin; and, optionally, (c) an antigenic molecule. The antigenic molecule displays the antigenicity of an antigen of: (a) a cell that elicits an autoimmune response; (b) an agent of an infectious disease; (c) a cancerous cell; or (d) a cell or structure associated with a neurodegenerative or amyloid disease. The hsps that can be used in the practice of the invention include but are not limited to hsp70, hsp90, gp96, calreticulin, hsp 110, grp 170, and PDI, alone or in combination with each other. The antigenic molecule can be covalently or noncovalently bound to the hsp or alpha2M, free in solution, and/or covalently bound to the saponin. The compositions of the invention can be administered alone or in combination with the administration of antigen presenting cells sensitized with an hsp- or alpha2M-antigenic molecule complex.

The present invention relates to dermal vaccine formulations, designed for targeted delivery of an immunogenic composition to a dermal compartment of skin including the intradermal and epidermal compartments. The dermal vaccine formulations of the invention comprise an antigenic or immunogenic agent, and at least one molecule, e.g., a chemical agent, which enhances the presentation and/or availability of the antigenic or immunogenic agent to the immune cells of the intradermal compartment or epidermal compartment resulting in an enhanced immune response. The dermal vaccine formulations of the invention have enhanced efficacy as the antigenic or immunogenic agent is delivered to the intradermal compartment or epidermal compartment with enhanced presentation and/or availability to the immune cells that reside therein. The enhanced efficacy of the dermal vaccine formulations results in a therapeutically effective immune response after a single intradermal or epidermal dose, with lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations.

This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.

The invention relates to a bracket material used for an osseous tissue project, and a preparation method thereof. Firstly, the bracket of a type I collagen is extracted from a small fresh pigskin by a mature extracting technique. Then, the bracket is further expanded in a Tris cushion liquid, the pH of which is equal to 8.8 to obtain a natural porous collagen bracket by the treatments of freezing and drying. The bracket is respectively and repeatedly mineralized in a CaCl2 liquid and in (NH4)2HPO4 liquid or mineralized in simulated body fluid for a long period to lead the weakly crystallized HA to be uniformly settled into the collagen bracket; and then a pigskin collagen-hydroxyapatite ossein is obtained by the treatments of freezing and drying to replace the natural bracket material. The invention not only maintains the natural bracket structure of the collagen in an organism, but also has the advantages of low material cost, simple devices, short period and easy operation. The obtained compound bracket material used for the pigskin collagen-hydroxyapatite osseous tissue project has the characteristics of high intensity, large toughness, non-antigenicity, higher biological activity as well as degradation and releasing control.

The invention discloses a three-dimensional porous cartilage extracellular matrix sponge scaffold made of natural cartilage, which can compound cells further to construct tissue engineered cartilage, and can be used for clinically repairing cartilage defects. In the invention, conditions which can fully perform cell extraction and form a porous scaffold matrix are provided by processing cartilage into cartilage microfilaments, and then the cell extraction and solidification and/or strengthening treatment are performed to obtain the three-dimensional porous cartilage extracellular matrix sponge scaffold which is completely decellurized. The antigenicity and cell components are removed in the natural cartilage, and an extracellular matrix component of the cartilage is retained to obtain the scaffold with appropriate pore diameter and porosity, suitable degradation rate, good biocompatibility and certain biomechanical strength. The scaffold has the advantages of broad material sources, low cost, simple and feasible preparation technology, and good repetitiveness; and the scaffold can be widely applied in the field of tissue engineering and has good clinical application prospect.

The invention relates to a guided tissue regeneration membrane, which comprises a compact coating and a loose coating, wherein the compact coating is composed of collagen-I or collagen-I composite hyaluronic acid; and the loose coating is composed of collagen-I or collagen-I composite calcium salt. A preparation method of the guided tissue regeneration membrane comprises the following steps of: preparing a collagen solution or a collagen and hyaluronic acid mixed solution by the use of acetic acid; injecting the solution into a self-made die, and drying it in the air to prepare the compact coating; injecting the collagen solution or a mixed liquor of the collagen solution and calcium salt onto the compact coating, and uniformly spreading; precooling the die at ultralow temperature, followed by freeze-drying to prepare the guided membrane with the compact coating and loose coating structure; carrying out vacuum high-temperature crosslinking and chemical crosslinking; and finally cleaning. The regeneration membrane has good histocompatibility and mechanical strength, low antigenicity and strong guided tissue regeneration capability. Its degradation rate in vivo is 3-8 months. The method is easy to operate, is suitable for automatic and continuous large-scale production, and solves the problems of large size of collagen membrane and material uniformity during industrial production.

An apparatus for sectioning fresh unfixed tissue into very thin layers with preserved tissue architecture, antigenicity, mRNA content, and amenable to 3-D computer reconstruction without mechanical or thermal damage by employing a sectioning tool having an electrode with an intense focused electrical field at an edge. A computer controlled x-y-z translation stage moves the sectioning tool through the tissue as defined by a predetermined program. The sectioning tool produces consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analyses without mechanical or thermal damage, ultimately allowing high-resolution volumetric reconstruction of gene and protein expression patterns of large tissue specimens. The geometry of the sectioning tool is selected so as to produce a spatially localized electrical field of sufficient intensity to sever molecular bonds or propagate flaws in tissue without mechanical cutting.

Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.

The present invention relates to compositions for intradermal delivery of an antigenic or immunogenic agent in combination with one or more adjuvants. The immunogenic compositions of the invention comprise an antigenic or immunogenic agent and at least one adjuvant, which enhances the immune response to the antigenic or immunogenic agent, once delivered to the intradermal compartment of a subject's skin. The immunogenic compositions of the invention have enhanced efficacy as the adjuvants of the composition promote recruitment of antigen presenting cells to the intradermal compartment and thus enhance presentation and/or availability of the antigenic or immunogenic agent to the antigen presenting cells. The enhanced efficacy of the immunogenic compositions of the invention results in a therapeutically and/or prophylactically effective immune response after a single intradermal dose, with lower doses of adjuvant than conventionally used, achieving therapeutic efficacy from a single administration.

The invention mainly aims to provide a porcine circovirus type 2 (PCV2) subunit vaccine and a preparation method thereof. Particularly, a baculovirus vector expression system is utilized to express a large amount of recombinant open reading frame type 2 (ORF2) protein in insect cells, so that the subunit vaccine with good immunity effect is developed. A bac-to-bac baculovirus expression system is adopted to perform whole gene amplification on the porcine circovirus type 2 ORF2 gene, and a melittin signal peptide nucleotide sequence is introduced into a terminal 5', so that the recombinant baculovirus of an open reading frame containing the melittin signal peptide nucleotide sequence and a PVC2ORF2 gene sequence is established, wherein the infected insect cell expresses the recombinant ORF2 protein with efficient and high PCV2 antigenicity; and thus the subunit vaccine containing the PCV2 recombinant ORF2 protein is prepared. The inoculation experiments of piglets show that the subunit vaccine has a good immunity protection effect.

The invention relates to a medical compound micropore polysaccharide and application in hemostasis on wound surface bleeding areas of various wounds and operation tissues. The medical compound micropore polysaccharide is prepared by adopting a method with the following steps: (1) preparing starch fluid; (2) preparing carboxymethyl chitosan solution; (3) mixing the starch fluid and the carboxymethyl chitosan solution, and adding dispersant and emulsifier into the mixture; (4) emulsifying, crosslinking and co-polymerizing; and (5) refining, drying, packing and sterile treatment. The invention also discloses application of the medical compound micropore polysaccharide in preparing a hemostasis medicament used for the wound surface bleeding areas of wounds and operation tissues. The medical compound micropore polysaccharide of the invention has the following characteristics: 1, the hemostasis time is short, namely the hemostasis is generally finished in 3 to 5 minutes; 2, the medical compound micropore polysaccharide has no antigenicity, has polysaccharide components, and has no protein or immune reaction; 3, the medical compound micropore polysaccharide can be fully degraded and absorbed in vivo; 4, the medical compound micropore polysaccharide is a sterile product and is convenient to use by opening; and 5, the tissue reaction is light. Therefore, the medical compound micropore polysaccharide is a comparatively ideal surgical hemostasis product.

The invention discloses a tissue engineering bone/cartilage double-layer scaffold and a construction method and application in medical science. The method adopts natural cartilage and bone as materials, respectively removes the antigenicity of the cartilage and the bone through de-cell, and adopts a freezing and drying method to prepare the double-layer scaffold simultaneously suitable for growthof the two issues of the bone and the cartilage. A preparation method comprises that: acellular bone is soaked in suspension of cartilage acellular matrix microfilaments, and the double-layer scaffoldof which the upper layer is a cartilage acellular matrix three-dimensional porous spongy scaffold and the lower layer is an acellular bone scaffold is prepared by the freezing and drying method and acrosslinking method. The cartilage acellular matrix spongy scaffold part of the double-layer scaffold can be introduced with factors promoting the formation of the cartilage, and the acellular bone part can be introduced with factors promoting the formation of the bone, and the factors can be respectively inoculated with cells for forming the cartilage or the bone to construct a living tissue engineering bone/cartilage complex, which is used for repairing bone and cartilage complex defect or total joint defect clinically.